References
- Kemp K C, Hows J, Donaldson C. Bone marrow-derived mesenchymal stem cells. Leukemia and Lymphoma 2005; 46(11)1531–1544
- Valent P, Akin C, Sperr W, Mayerhofer M, Födinger M, Fritsche-Polanz R, Sotlar K, Escribano L, Arock M, Horny H, Metcalfe D. Mastocytosis: Pathology, genetics, and current options for therapy. Leukemia and Lymphoma 2005; 46(1)35–48
- Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos M. Clinical implications of chromosomal abnormalities in multiple myeloma. Leukemia and Lymphoma 2006; 47(5)803–814
- Nelson M E, Steensma D P. JAK2 V617F in myeloid disorders: What do we know now, and where are we headed?. Leukemia and Lymphoma 2006; 47(2)177–194
- Ganjoo K N, An C S, Robertson M J, Gordon L I, Sen J A, Weisenbach J, Li S, Weller E A, Orazi A, Horning S J. Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leukemia and Lymphoma 2006; 47(6)998–1005
- Bouley J, Deriano L, Delic J, Merle-Béral H. New molecular markers in resistant B-CLL. Leukemia and Lymphoma 2006; 47(5)791–801
- Thiele J, Kvasnicka H M. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leukemia and Lymphoma 2006; 47(3)381–396
- Zent C S, Call T G, Hogan W J, Shanafelt T D, Kay N E. Update on risk-stratified management for chronic lymphocytic leukemia. Leukemia and Lymphoma 2006; 47(9)1738–1746
- Yanada M, Naoe T. Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: Major challenges in current practice. Leukemia and Lymphoma 2006; 47(9)1747–1753
- Corallini F, Milani D, Nicolin V, Secchiero P. TRAIL, caspases and maturation of normal and leukemic myeloid precursors. Leukemia and Lymphoma 2006; 47(8)1459–1468
- Tough D F. Type I Interferon as a Link Between Innate and Adaptive Immunity through Dendritic Cell Stimulation. Leukemia and Lymphoma 2004; 45(2)257–264
- Friedberg J W, Fischman A, Neuberg D, Kim H, Takvorian T, Ng A K, Mauch P M, Canellos G P, Abbeele A. FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients with de novo Hodgkin Lymphoma: A Blinded Comparison. Leukemia and Lymphoma 2004; 45(1)85–92
- Gottschalk S, Heslop H, Rooney C. Adoptive Immunotherapy for EBV-associated Malignancies. Leukemia and Lymphoma 2005; 46(1)1–10
- Kim S, Chow K, Kukoc-Zivojnov N, Boehrer S, Brieger A, Steimle-Grauer S, Harder L, Hoelzer D, Mitrou P, Weidmann E. Expression of ZAP-70 Protein Correlates with Disease Stage in Chronic Lymphocytic Leukemia and is Associated with, but not Generally Restricted to, Non-mutated Ig VH Status. Leukemia and Lymphoma 2004; 45(10)2037–2045
- Slape C, Aplan P D. The Role of NUP98 Gene Fusions in Hematologic Malignancy. Leukemia and Lymphoma 2004; 45(7)1341–1350
- Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved Outcome of Zygomycosis in Patients with Hematological Diseases?. Leukemia and Lymphoma 2004; 45(7)1351–1360
- Gertz M A, Rue M, Blood E, Kaminer L S, Vesole D H, Greipp P R. Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leukemia and Lymphoma 2004; 45(10)2047–2055
- Matthews C, Catherwood M A, Morris T, Alexander H. Routine Analysis of IgVH Mutational Status in CLL Patients using BIOMED-2 Standardized Primers and Protocols. Leukemia and Lymphoma 2004; 45(9)1899–1904
- Mainou-Fowler T, Dignum H M, Proctor S J, Summerfield G P. The Prognostic Value of CD38 Expression and its Quantification in B Cell Chronic Lymphocytic Leukemia (B-CLL). Leukemia and Lymphoma 2004; 45(3)455–462
- Hakansson A. The Impact Factor – A dubious measure of scientific quality. Scand J Prim Health Care 2005; 23: 193–194